EMB-driven glioblastoma multiforme progression via the MCT4/GPX3 axis: therapeutic inhibition by Ganxintriol A
This study highlights EMB as an independent prognostic biomarker for GBM and reveals a novel mechanism by which EMB drives GBM progression. Additionally, Ganxintriol A is identified as a promising therapeutic candidate for GBM treatment.
Authors
- Ziwen Zhu (ORCID: https://orcid.org/0000-0002-6681-9153)
- Ling Gao (ORCID: https://orcid.org/0000-0002-5033-0433)
- Xiaojin Wu (ORCID: https://orcid.org/0000-0003-3894-0631)
- Sifeng Liu (ORCID: https://orcid.org/0000-0002-5872-9457)
- Yang Yang (ORCID: https://orcid.org/0000-0003-4518-6411)
- Bo Cheng (ORCID: https://orcid.org/0000-0001-9551-1142)
- Jing Liu (ORCID: https://orcid.org/0000-0002-7483-4572)
Institutions
- Tongji University (CN)
- Xuzhou Medical College (CN)
- Xuzhou Central Hospital (CN)
- Xuzhou No.1 People's Hospital (CN)
- Tongji Hospital (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1186/s12967-025-06290-z
- Citations
- 3
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Xuzhou Science and Technology Bureau